Neurocrine Biosciences, Inc. $NBIX Stock Holdings Increased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 86.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,185 shares of the company’s stock after purchasing an additional 13,087 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Neurocrine Biosciences were worth $3,957,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Earned Wealth Advisors LLC lifted its position in shares of Neurocrine Biosciences by 53.8% during the 3rd quarter. Earned Wealth Advisors LLC now owns 2,465 shares of the company’s stock valued at $346,000 after acquiring an additional 862 shares during the last quarter. Asset Management One Co. Ltd. raised its position in shares of Neurocrine Biosciences by 0.8% during the third quarter. Asset Management One Co. Ltd. now owns 40,872 shares of the company’s stock worth $5,738,000 after purchasing an additional 311 shares during the period. Fulton Bank N.A. lifted its holdings in shares of Neurocrine Biosciences by 37.5% during the third quarter. Fulton Bank N.A. now owns 3,644 shares of the company’s stock valued at $512,000 after purchasing an additional 993 shares during the last quarter. Financiere des Professionnels Fonds d investissement inc. boosted its position in shares of Neurocrine Biosciences by 60.0% in the 3rd quarter. Financiere des Professionnels Fonds d investissement inc. now owns 8,865 shares of the company’s stock valued at $1,244,000 after purchasing an additional 3,324 shares during the period. Finally, Altfest L J & Co. Inc. acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at $368,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Up 0.2%

Shares of NASDAQ:NBIX opened at $135.79 on Friday. The firm has a fifty day moving average of $146.36 and a two-hundred day moving average of $139.73. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $160.18. The firm has a market capitalization of $13.54 billion, a P/E ratio of 32.49, a price-to-earnings-growth ratio of 0.66 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.59. The business had revenue of $794.90 million during the quarter, compared to analyst estimates of $746.61 million. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.Neurocrine Biosciences’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same period last year, the company earned $1.81 earnings per share. Equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Neurocrine Biosciences

In other news, Director William H. Rastetter sold 18,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the completion of the sale, the director directly owned 40,360 shares in the company, valued at $6,127,455.20. The trade was a 30.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kyle Gano sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at approximately $19,933,581.79. The trade was a 0.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 43,866 shares of company stock worth $6,570,237. 4.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on NBIX. Royal Bank Of Canada upped their price objective on shares of Neurocrine Biosciences from $160.00 to $180.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Needham & Company LLC upped their price target on shares of Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Wednesday, October 8th. HC Wainwright boosted their target price on shares of Neurocrine Biosciences from $168.00 to $198.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Wedbush restated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.20.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.